eCite Digital Repository

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Citation

Lee, OL and Horvath, N and Lee, C and Joshua, D and Ho, J and Szer, J and Quach, H and Spencer, A and Harrison, S and Mollee, P and Roberts, AW and Talaulikar, D and Brown, R and Augustson, B and Ling, S and Jaksic, W and Gibson, J and Kalff, A and Johnston, AM and Kalro, A and Ward, Chris and Prince, HM and Zannettino, A, Bisphosphonate guidelines for treatment and prevention of myeloma bone disease, Internal Medicine Journal, 47, (8) pp. 938-951. ISSN 1444-0903 (2017) [Refereed Article]

Copyright Statement

2017 Royal Australasian College of Physicians

DOI: doi:10.1111/imj.13502

Abstract

Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal-related events such as pathologic fracture, spinal cord compression and hypercalcaemia. MBD is the result of MM plasma cells-mediated activation of osteoclast activity and suppression of osteoblast activity. Bisphosphonates (BP), pyrophosphate analogues with high bone affinity, are the only pharmacological agents currently recommended for the treatment and prevention of MBD and remain the standard of care. Pamidronate and zoledronic acid are the most commonly used BP to treat MBD. Although generally safe, frequent high doses of BP are associated with adverse events such as renal toxicity and osteonecrosis of the jaw. As such, optimal duration and dosing of BP therapy is required in order to minimise BP-associated adverse events. The following guidelines provide currently available evidence for the adoption of a tailored approach when using BP for the management of MBD.

Item Details

Item Type:Refereed Article
Keywords:myeloma, bisphosphonate, skeletal-relatedevent (SRE), osteolysis, osteoblast, osteoclast
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Haematology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Roberts, AW (Professor Andrew Roberts)
UTAS Author:Johnston, AM (Dr Anna Johnston)
UTAS Author:Prince, HM (Associate Professor H. Prince)
ID Code:152351
Year Published:2017
Web of Science® Times Cited:13
Deposited By:Medicine
Deposited On:2022-08-17
Last Modified:2022-09-21
Downloads:0

Repository Staff Only: item control page